Please assess the completion status of the following clinical trial:

Trial Title: Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~Subjects eligible for enrollment in the study must meet all of the following criteria:~* Patients with upper limb spasticity who are at least 6 months post stroke and present with spasticity of both the wrist and fingers at the start of double-blind phase (Visit 2).~* Wrist flexor muscle tone of ≥3 and finger flexor muscle tone of ≥2 on the MAS, and at least one functional disability item (i.e., hygiene, pain, dressing or limb posture) with a rating of ≥2 on the Disabilty Assessment Scale (DAS) at the start of double-blind phase (Visit 2).~* Male or female between 20 and 80 years of age at the time of informed consent. For males, only those who can practice contraception during the study period are eligible.~* ≥40kg in weight at the start of double-blind phase (Visit 2).~* Inpatient or outpatient; however, the hospitalization status must remain unchanged during the double-blind phase.~* Written informed consent from the subject him/herself. If the subject's signature is not legible, the attendance of a witness is required.~Exclusion Criteria:~* A subject will not be eligible for inclusion in this study if any of the following criteria apply:~* Bilateral hemiplegia or quadriplegia.~* Presence of fixed contractures of the wrist and/or fingers (absence of range of motion).~* Profound atrophy of the muscles to be injected.~* Previous surgical intervention, phenol block, ethanol block, or muscle afferent block (MAB) for wrist and/or finger spasticity.~* Casting of the study upper limb within 3 months prior to the start of double-blind phase (Visit 2).~* Current treatment with intrathecal baclofen.~* Use of peripheral muscle relaxants (dantrolene sodium, suxamethonium chloride, pancuronium bromide, vecuronium bromide, rocuronium bromide).~* Concurrent use of antibiotics that interfere with neuromuscular transmission, such as aminoglycoside antibiotics (e.g., streptomycin sulfate, kanamycin sulfate, gentamicin sulfate, neomycin sulphate, spectinomycin hydrochloride), polypeptide antibiotics (e.g., polymixin B sulfate), lincomycin antibiotics (e.g., lincomycin hydrochloride, clindamycin), and enviomycin sulfate.~* Previous botulinum toxin therapy.~* Diagnosis of systemic neuromuscular disorders (e.g., myasthenia gravis, Lambert-Eaton syndrome, amyotrophic lateral sclerosis).~* Females who are pregnant, nursing, may be pregnant, or planning a pregnancy during the study period.~* Known allergy or hypersensitivity to any ingredient of study medication (e.g., human serum albumin).~* Presence of psychiatric disorder or impairment of intellectual function that may interfere with the subject's ability to give informed consent or the conduct of the study.~* Bedridden patients.~* Presence of clinically unstable severe cardiovascular disease.~* Presence of clinically significant severe renal, hepatic or respiratory disease.~* Infection or dermatological condition at the proposed injection sites.~* Previous or planned participation in another clinical study (including the lower limb spasticity study of GSK1358820) within 6 months prior to the start of double-blind phase (Visit 2).~* Others whom the investigator or sub investigator considers not eligible for the study.~* Clinically significant severe reduction of muscle strength.~* Angle closure glaucoma or its preposition (narrow angle).

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- High-Dose BTX (Type: ACTIVE_COMPARATOR): None
- High-Dose Placebo (Type: PLACEBO_COMPARATOR): None
- Low-Dose BTX (Type: ACTIVE_COMPARATOR): None
- Low-Dose Placebo (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).